nference launches real-world data platform, expands partnership with Mayo Clinic

Data firm EHR nference on Wednesday launched its real-world proof-of-concept platform and expands on an existing partnership with the Mayo Clinic.

The platform, called nSights, collects unidentified patient clinical data from academic medical centers, including clinical notes, radiology results, lab tests and electrocardiogram. The company says it will eventually add digital pathology and genomic data as well. nference is introducing the platform as a way for researchers to develop therapeutics and diagnostics using data collected from nSights.

The company is also expanding its 12-year strategic partnership with the Mayo Clinic, providing nference customers and partners with access to the Mayo Clinic Platform’s unidentified electronic health data. They will also build a Mayo Clinic-branded version of the nSights platform, called Mayo Clinic Platform_Discover.

Mike Koenig, commercial director at the nference, said: “The potential of e-health data remains limited in health centers and is often under-exploited due to the complexity of the data, its relationships and relationships. privacy and security concerns”. “Our expanded partnership with the Mayo Clinic Platform provides the framework for nference’s nSights implementation and gives our customers access to defined ‘patient-level’ data to advance I look forward to continuing to build and strengthen the partnership with the Mayo Clinic team as we work together to improve healthcare through knowledge and data-driven insights.”


As soon as the nference closes a Series B round worth $60 million in early 2020, Mayo Clinic announces its first startup Clinical Data Analytics Platform Partner. Mayo Clinic Ventures participated as a strategic investor in that capital raise and also participated $60 million Series C ends at the end of 2020.

They have also collaborated on Research on a vaccine for COVID-19 and expand their partnership including digital pathology and heart rate diagnostics. Last year, they founded Anumana with the goal of using nference’s AI capabilities and Mayo’s medical data to build digital sensor diagnostics, starting with heart disease detection.

Anumana got it FDA Breakthrough Device Designation This spring for an ECG-based AI algorithm for early detection of pulmonary hypertension. It also partnered with pharmaceutical giant Novartis to develop AI tools to detect cardiovascular diseases.

Source link


Goz News: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably.

Related Articles

Back to top button